ArticleBritish journal of haematology2025
Prevalence of myeloid gene alterations in paediatric cutaneous and systemic mastocytosis.
Article in British journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Systemic Mastocytosis, KIT and the Effects of KIT Tyrosine Kinase Inhibitors on Mast Cell and Basophil Activation.Current allergy and asthma reports · 2026Review
- Molecular characterization of pediatric mastocytosis revealed different somatic mutations with uncertain prognostic value.Frontiers in cell and developmental biology · 2026Article
- Prevalence of myeloid gene alterations in paediatric cutaneous and systemic mastocytosis.British journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Paediatric mastocytosis is a heterogeneous disorder with different clinical subtypes and an often indolent disease course. The molecular landscape of genetic mutations, beyond KIT D816V, remains under exploration. We thus investigated the prevalence of myeloid genetic mutations in peripheral blood samples of 69 paediatric patients with cutaneous mastocytosis and systemic mastocytosis (SM) using next-generation sequencing. KIT D816V was exclusively found in those with SM, while other KIT mutations (D419del, A502_Y503dup, Y503_A507dup, G565V and N822H) were only detected in those with cutaneous disease. Although no other common non-KIT myeloid mutations were shared among patients, we identified 64 non-synonymous coding genetic mutations across 30 genes, including 15 classified as pathogenic/likely pathogenic, with none occurring in SRSF2 and ASXL1. Most of these pathogenic/likely pathogenic non-KIT mutations (86.7%) were found in paediatric patients with SM. In summary, we discovered a number of non-KIT myeloid alterations in paediatric mastocytosis and which were more common in children with systemic disease. Variant allele frequency of many of these gene alterations was about 50% or 100%, suggesting germline in nature. The long-term impact of these additional genetic alterations on disease course is uncertain at present and supports the need for assessment in long-term follow-up studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.